Inhibition of tumor angiogenesis is a promising approach in cancer treatment. The purpose
of this study was to evaluate the vascular response of human lung tumor xenografts in vivo …

It has been> 35 years since the link between angiogenesis and the growth of tumors was
first reported. Targeting angiogenesis became feasible with the availability of bevacizumab …

Glioma is the most common primary brain tumor and has an undesirable prognosis due to
the blood-brain barrier (BBB) and drug resistance. A thorough investigation of the changes …

B248 Background: XL880 is a potent orally available small molecule inhibitor of MET and
VEGFR2/KDR, that also inhibits PDGFR, KIT, FLT3, and Tie-2. Significant tumor growth …

BMS‐690514, a selective inhibitor of the ErbB and vascular endothelial growth factor
receptors, has shown antitumor activity in early clinical development. The compound is …

Oncolytic viruses (OVs) are considered a promising therapeutic alternative for cancer.
However, despite the development of novel OVs with improved efficacy and tumor …

Noninvasive imaging has been widely applied for monitoring antiangiogenesis therapy in
cancer drug discovery. In this report, we used different imaging modalities including high …

Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016
is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor …

There are few predictive biomarkers for antiangiogenic trials in lung cancer. We examine a
potential treatment strategy in which a patient group is enriched using both histology and an …

The inhibition of tumor angiogenesis is a key therapeutic strategy that holds great promise
for the advancement of metastatic lung cancer therapy. The combination of bevacizumab …